Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

This Phase 1/2 study is testing a new drug called PEEL-224 combined with two chemotherapy drugs (vincristine and temozolomide) in teenagers and young adults with sarcomas — bone and soft tissue cancers — that have returned or stopped responding to standard treatment. **You may be eligible if...** - Your sarcoma has relapsed or is no longer responding to standard therapy - For Phase 1: you have any type of sarcoma with measurable or detectable disease - For Phase 2 (Ewing sarcoma group): you have confirmed Ewing sarcoma with a specific genetic translocation and measurable disease - For Phase 2 (DSRCT group): you have confirmed desmoplastic small round cell tumor with measurable disease **You may NOT be eligible if...** - Your sarcoma has not yet failed standard treatment - You do not have measurable disease - You have conditions that make the combination treatment unsafe Talk to your doctor to see if this trial is right for you.